1. Report Introduction 2. Immune thrombocytopenia (ITP) Market Overview at a Glance 2.1. Market Share Distribution of Immune thrombocytopenia (ITP) in 2017 2.2. Market Share Distribution of Immune thrombocytopenia (ITP) in 2028 3. Disease Background and Overview: Immune thrombocytopenia (ITP) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Immune thrombocytopenia (ITP) in 7MM 4.3. Total Prevalent Patient Population of Immune thrombocytopenia (ITP) in 7MM – By Countries 5. Epidemiology of Immune thrombocytopenia (ITP) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) 5.1.3. Sub-Type Specific cases of the Immune thrombocytopenia (ITP) *Indication Specific 5.1.4. Sex- Specific Cases of the Immune thrombocytopenia (ITP)*Indication Specific 5.1.5. Diagnosed Cases of the Immune thrombocytopenia (ITP) 5.1.6. Treatable Cases of the Immune thrombocytopenia (ITP) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) 5.4.3. Sub-Type Specific cases of the Immune thrombocytopenia (ITP)* 5.4.4. Sex- Specific Cases of the Immune thrombocytopenia (ITP)* 5.4.5. Diagnosed Cases of the Immune thrombocytopenia (ITP) 5.4.6. Treatable Cases of the Immune thrombocytopenia (ITP) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) 5.5.3. Sub-Type Specific cases of the Immune thrombocytopenia (ITP)* 5.5.4. Sex- Specific Cases of the Immune thrombocytopenia (ITP)* 5.5.5. Diagnosed Cases of the Immune thrombocytopenia (ITP) 5.5.6. Treatable Cases of the Immune thrombocytopenia (ITP) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) 5.6.3. Sub-Type Specific cases of the Immune thrombocytopenia (ITP)* 5.6.4. Sex- Specific Cases of the Immune thrombocytopenia (ITP)* 5.6.5. Diagnosed Cases of the Immune thrombocytopenia (ITP) 5.6.6. Treatable Cases of the Immune thrombocytopenia (ITP) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) 5.7.3. Sub-Type Specific cases of the Immune thrombocytopenia (ITP)* 5.7.4. Sex- Specific Cases of the Immune thrombocytopenia (ITP)* 5.7.5. Diagnosed Cases of the Immune thrombocytopenia (ITP) 5.7.6. Treatable Cases of the Immune thrombocytopenia (ITP) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) 5.8.3. Sub-Type Specific cases of the Immune thrombocytopenia (ITP)* 5.8.4. Sex- Specific Cases of the Immune thrombocytopenia (ITP)* 5.8.5. Diagnosed Cases of the Immune thrombocytopenia (ITP) 5.8.6. Treatable Cases of the Immune thrombocytopenia (ITP) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) 5.9.3. Sub-Type Specific cases of the Immune thrombocytopenia (ITP)* 5.9.4. Sex- Specific Cases of the Immune thrombocytopenia (ITP)* 5.9.5. Diagnosed Cases of the Immune thrombocytopenia (ITP) 5.9.6. Treatable Cases of the Immune thrombocytopenia (ITP) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Immune thrombocytopenia (ITP) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Immune thrombocytopenia (ITP) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Immune thrombocytopenia (ITP): 7MM Market Analysis 12.1. 7MM Market Size of Immune thrombocytopenia (ITP) 12.2. 7MM Percentage Share of drugs marketed for Immune thrombocytopenia (ITP) 12.3. 7MM Market Sales of Immune thrombocytopenia (ITP) by Products 13. Immune thrombocytopenia (ITP): Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Immune thrombocytopenia (ITP) in United States 13.1.2. Percentage Share of drugs marketed for Immune thrombocytopenia (ITP) in United States 13.1.3. Market Sales of Immune thrombocytopenia (ITP) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Immune thrombocytopenia (ITP) in Germany 13.2.1.2. Percentage Share of drugs marketed for Immune thrombocytopenia (ITP) in Germany 13.2.1.3. Market Sales of Immune thrombocytopenia (ITP) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Immune thrombocytopenia (ITP) in France 13.2.2.2. Percentage Share of drugs marketed for Immune thrombocytopenia (ITP) in France 13.2.2.3. Market Sales of Immune thrombocytopenia (ITP) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Immune thrombocytopenia (ITP) in Italy 13.2.3.2. Percentage Share of drugs marketed for Immune thrombocytopenia (ITP) in Italy 13.2.3.3. Market Sales of Immune thrombocytopenia (ITP) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Immune thrombocytopenia (ITP) in Spain 13.2.4.2. Percentage Share of drugs marketed for Immune thrombocytopenia (ITP) in Spain 13.2.4.3. Market Sales of Immune thrombocytopenia (ITP) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Immune thrombocytopenia (ITP) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Immune thrombocytopenia (ITP) in United Kingdom 13.2.5.3. Market Sales of Immune thrombocytopenia (ITP) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Immune thrombocytopenia (ITP) in Japan 13.3.2. Percentage Share of drugs marketed for Immune thrombocytopenia (ITP) in Japan 13.3.3. Market Sales of Immune thrombocytopenia (ITP) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight

Table 1: Total Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in 7MM Table 2: Total Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in United States (2017-2028) Table 4: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in United States (2017-2028) Table 5: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in United States (2017-2028) Table 6: Diagnosed Cases of the Immune thrombocytopenia (ITP) in United States (2017-2028) Table 7: Treatable Cases of the Immune thrombocytopenia (ITP) in United States (2017-2028) Table 8: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in Germany (2017-2028) Table 9: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in Germany (2017-2028) Table 10: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in Germany (2017-2028) Table 11: Diagnosed Cases of the Immune thrombocytopenia (ITP) in Germany (2017-2028) Table 12: Treatable Cases of the Immune thrombocytopenia (ITP) in Germany (2017-2028) Table 13: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in France (2017-2028) Table 14: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in France (2017-2028) Table 15: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in France (2017-2028) Table 16: Diagnosed Cases of the Immune thrombocytopenia (ITP) in France (2017-2028) Table 17: Treatable Cases of the Immune thrombocytopenia (ITP) in France (2017-2028) Table 18: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in Italy (2017-2028) Table 19: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in Italy (2017-2028) Table 20: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in Italy (2017-2028) Table 21: Diagnosed Cases of the Immune thrombocytopenia (ITP) in Italy (2017-2028) Table 22: Treatable Cases of the Immune thrombocytopenia (ITP) in Italy (2017-2028) Table 23: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in Spain (2017-2028) Table 24: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in Spain (2017-2028) Table 25: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in Spain (2017-2028) Table 26: Diagnosed Cases of the Immune thrombocytopenia (ITP) in Spain (2017-2028) Table 27: Treatable Cases of the Immune thrombocytopenia (ITP) in Spain (2017-2028) Table 28: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in UK (2017-2028) Table 29: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in UK (2017-2028) Table 30: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in UK (2017-2028) Table 31: Diagnosed Cases of the Immune thrombocytopenia (ITP) in UK (2017-2028) Table 32: Treatable Cases of the Immune thrombocytopenia (ITP) in UK (2017-2028) Table 33: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in Japan (2017-2028) Table 34: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in Japan (2017-2028) Table 35: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in Japan (2017-2028) Table 36: Diagnosed Cases of the Immune thrombocytopenia (ITP) in Japan (2017-2028) Table 37: Treatable Cases of the Immune thrombocytopenia (ITP) in Japan (2017-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Table 42:7MM- Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 43:7MM- Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 44: United States-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Table 45: United States-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 46: United States-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 47: Germany-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Table 48: Germany-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 49: Germany-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 50: France-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Table 51: France-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 52: France-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 53: Italy-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Table 54: Italy-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 55: Italy-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 56: Spain-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Table 57: Spain-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 58: Spain-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 59:UK-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Table 60:UK-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 61:UK-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 62: Japan-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Table 63: Japan-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Table 64: Japan-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 1: Total Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in 7MM Figure 2: Total Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in United States (2017-2028) Figure 4: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in United States (2017-2028) Figure 5: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in United States (2017-2028) Figure 6: Diagnosed Cases of the Immune thrombocytopenia (ITP) in United States (2017-2028) Figure 7: Treatable Cases of the Immune thrombocytopenia (ITP) in United States (2017-2028) Figure 8: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in Germany (2017-2028) Figure 9: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in Germany (2017-2028) Figure 10: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in Germany (2017-2028) Figure 11: Diagnosed Cases of the Immune thrombocytopenia (ITP) in Germany (2017-2028) Figure 12: Treatable Cases of the Immune thrombocytopenia (ITP) in Germany (2017-2028) Figure 13: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in France (2017-2028) Figure 14: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in France (2017-2028) Figure 15: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in France (2017-2028) Figure 16: Diagnosed Cases of the Immune thrombocytopenia (ITP) in France (2017-2028) Figure 17: Treatable Cases of the Immune thrombocytopenia (ITP) in France (2017-2028) Figure 18: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in Italy (2017-2028) Figure 19: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in Italy (2017-2028) Figure 20: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in Italy (2017-2028) Figure 21: Diagnosed Cases of the Immune thrombocytopenia (ITP) in Italy (2017-2028) Figure 22: Treatable Cases of the Immune thrombocytopenia (ITP) in Italy (2017-2028) Figure 23: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in Spain (2017-2028) Figure 24: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in Spain (2017-2028) Figure 25: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in Spain (2017-2028) Figure 26: Diagnosed Cases of the Immune thrombocytopenia (ITP) in Spain (2017-2028) Figure 27: Treatable Cases of the Immune thrombocytopenia (ITP) in Spain (2017-2028) Figure 28: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in UK (2017-2028) Figure 29: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in UK (2017-2028) Figure 30: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in UK (2017-2028) Figure 31: Diagnosed Cases of the Immune thrombocytopenia (ITP) in UK (2017-2028) Figure 32: Treatable Cases of the Immune thrombocytopenia (ITP) in UK (2017-2028) Figure 33: Prevalent/Incident Cases of the Immune thrombocytopenia (ITP) in Japan (2017-2028) Figure 34: Sub-Type Specific cases of the Immune thrombocytopenia (ITP) in Japan (2017-2028) Figure 35: Sex- Specific Cases of the Immune thrombocytopenia (ITP) in Japan (2017-2028) Figure 36: Diagnosed Cases of the Immune thrombocytopenia (ITP) in Japan (2017-2028) Figure 37: Treatable Cases of the Immune thrombocytopenia (ITP) in Japan (2017-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Figure 42:7MM- Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 43:7MM- Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 44: United States-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Figure 45: United States-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 46: United States-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 47: Germany-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Figure 48: Germany-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 49: Germany-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 50: France-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Figure 51: France-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 52: France-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 53: Italy-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Figure 54: Italy-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 55: Italy-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 56: Spain-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Figure 57: Spain-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 58: Spain-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 59:UK-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Figure 60:UK-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 61:UK-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 62: Japan-Market Size of Immune thrombocytopenia (ITP) in USD MM (2017-2028) Figure 63: Japan-Market Share Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028) Figure 64: Japan-Market Sales of Immune thrombocytopenia (ITP) by Therapies in USD MM (2017-2028)